Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of treating ischemic disorders

a technology of ischemic disorders and ischemic recurrence, applied in the field of ischemic recurrence treatment, can solve the problems of reduced substrate supply, accumulation of metabolites, atrophy, denaturation, necrosis of affected tissues, etc., and achieve the effect of increasing the number of stem cells and/or progenitor cells in the peripheral blood

Inactive Publication Date: 2010-07-01
THE CLEVELAND CLINIC FOUND
View PDF46 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]In an aspect of the invention, the number of stem cells and / or progenitor cells in the peripheral blood can be increased by injecting stem cells and / or progenitor cells into the peripheral blood and / or arterial or venous infusion of the stem cells into the mammalian subject being treated. One example of a particular type of stem cell that can be injected or infused in accordance with the present invention is an autologous mesenchymal stem cell (MSC). An example of a progenitor cell that can be potentially injected or infused is a autologous, syngeneic, or allogeneic bone marrow derived multipotent adult progenitor cell (MAPC).

Problems solved by technology

Ischemia is a condition wherein the blood flow is completely obstructed or considerably reduced in localized parts of the body, resulting in anoxia, reduced supply of substrates and accumulation of metabolites.
Although the extent of ischemia depends on the acuteness of vascular obstruction, its duration, tissue sensitivity to it, and developmental extent of collateral vessels, dysfunction usually occurs in ischemic organs or tissues, and prolonged ischemia results in atrophy, denaturation, apoptosis, and necrosis of affected tissues.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating ischemic disorders
  • Method of treating ischemic disorders
  • Method of treating ischemic disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

SDF-1 Expression by Mesenchymal Stem Cells Results in Trophic Support of Cardiac Myocytes Following Myocardial Infarction

[0151]The transplantation of multiple stem cell types at the time of myocardial infarction has been shown to improve left ventricular perfusion and / or function in preclinical and clinical studies. While this strategy holds great potential for the prevention and treatment of congestive heart failure, a condition that affects over 5 million Americans, the mechanisms behind the improvement remain unclear. One possibility is that the transplanted stem cells regenerate myocardial tissue by differentiating into cardiac myocytes, endothelial cells and smooth muscle cells. Another less explored possibility is that the introduction of stem cells into the myocardium at the time of acute myocardial infarction (AMI) supports the injured tissue through as yet undefined trophic effects leading to preservation of cardiac myocytes and improved cardiac function. If trophic effects...

example 2

MCP-3 is a Myocardial Mesenchymal Stem Cell Homing Factor

[0187]We have previously demonstrated that there is transient homing of hematopoietic stem cells (HSC) to the heart following myocardial infarction (MI). The transient nature of HSC homing is due, at least in part, to the transient expression of SDF-1. Whereas HSC seem not to transdifferentiate into cardiac tissue, MSC can acquire some properties of cardiomyocytes in vitro. Since MSC have also been shown to home to the heart early after MI, we hypothesized that there are similarly chemokine(s) temporally secreted by the myocardium that can attract MSC. The current study was to identify potential MSC homing factor(s) and to test their effect on myocardial function if stably expressed within the border zone of at a time remote from MI.

Materials and Methods

LAD Ligation:

[0188]The Animal Research Committee approved all animal protocols and all animals were housed in the AAALAC animal facility of the Cleveland Clinic Foundation. Lig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Disorderaaaaaaaaaa
Login to View More

Abstract

A method of treating an ischemic disorders in a subject includes administering stromal cell derived factor-1 (SDF-1) to ischemic tissue of the subject in an amount effective to inhibit apoptosis of cells of the tissue.

Description

RELATED APPLICATION[0001]This application claims priority from U.S. provisional patent application Ser. No. 60 / 921,044, filed on Mar. 30, 2007, the subject matter of which is incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to compositions and methods of treating disorders associated with ischemia and / or tissue injury.BACKGROUND OF THE INVENTION[0003]Ischemia is a condition wherein the blood flow is completely obstructed or considerably reduced in localized parts of the body, resulting in anoxia, reduced supply of substrates and accumulation of metabolites. Although the extent of ischemia depends on the acuteness of vascular obstruction, its duration, tissue sensitivity to it, and developmental extent of collateral vessels, dysfunction usually occurs in ischemic organs or tissues, and prolonged ischemia results in atrophy, denaturation, apoptosis, and necrosis of affected tissues.[0004]Ischemic cerebrovascular injury development mechanisms a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/12A61K38/19A61P9/10
CPCA61K38/195A61K48/0075A61K35/28A61P11/00A61P13/12A61P43/00A61P7/02A61P9/10
Inventor PENN, MARC S.
Owner THE CLEVELAND CLINIC FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com